^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yonsa (abiraterone acetate)

    i
    Associations
    News

    Trials

    Company:
    Churchill Pharma, Sun Pharma
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCI-2018-01054) (NCT03360721)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/06/2018
    Primary completion :
    04/30/2027
    Completion :
    04/30/2027
    PTEN
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • prednisone • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer (INNOVATE) (NCT04134260)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    03/05/2020
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    CD4
    |
    abiraterone acetate • prednisone • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (NCT04513717)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/15/2020
    Primary completion :
    12/31/2033
    Completion :
    12/31/2033
    CD4
    |
    abiraterone acetate • bicalutamide • Erleada (apalutamide) • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)